Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
DICUMAROL vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Category C
Category A/B
Anticoagulant
Anticoagulant